Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Leukemia, Lymphocytic, Chronic, B-Cell
View Full LandscapeTarget Indication
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical Trial
NCT02639910Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Zydelig
Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
View on EMA